Marstacimab Biosimilar - Research Grade

Human

TFPI

>1mg/ml

IgG1 - lambda2

CHO Cells

Befovacimab Biosimilar - Research Grade (ICH5381), Concizumab Biosimilar - Research Grade (ICH5447)

https://www.imgt.org/mAb-DB/

ICH3002

P10646

Blue ice

This is an unconjugated, non-therapeutic recombinant analog of marstacimab, built around the same molecular target, tissue factor pathway inhibitor (TFPI), and supplied strictly for research use only. It is not the clinical drug and is not intended for human or veterinary use. Marstacimab is an anti-TFPI monoclonal antibody developed to promote hemostasis in hemophilia by relieving TFPI-mediated inhibition of the coagulation cascade; this research-grade analog reproduces the antibody's target specificity so investigators can study TFPI biology and antibody-based TFPI neutralisation in controlled settings. It is useful as a reference and positive control in binding, blocking, and neutralisation assays, for in-vitro coagulation and cell-based studies, for benchmarking other anti-TFPI reagents, and for antibody engineering or ADC/ADCC method development. The product is offered as a human IgG1/lambda format at research grade with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options) and is available in bulk milligram-to-gram quantities to support assay development and preclinical workflows. Tissue factor pathway inhibitor (TFPI, UniProt P10646) is a Kunitz-type serine protease inhibitor that is the principal endogenous regulator of the initiation phase of the extrinsic coagulation cascade. It contains three tandem Kunitz domains: the second (K2) binds and inhibits activated factor X (FXa), and the first (K1) then engages the tissue factor-factor VIIa (TF-FVIIa) complex, producing a quaternary FXa-TFPI-TF-FVIIa inhibitory assembly that shuts down further thrombin generation. The third Kunitz domain and the basic C-terminus mediate cell-surface and cofactor interactions, including binding to protein S, which enhances TFPI-alpha activity. TFPI is expressed mainly by vascular endothelium and exists in alpha and beta isoforms. By dampening TF-driven coagulation, TFPI sets a threshold for clot initiation; antibodies that block TFPI lower this threshold and can rebalance hemostasis, which is the rationale behind anti-TFPI therapeutics.

Extrinsic pathway inhibitor, EPI, Lipoprotein-associated coagulation inhibitor, LACI, Tissue factor pathway inhibitor, TFPI1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks

Q: Is the Marstacimab biosimilar available in bulk mg to gram quantities?

A: Yes — it is manufactured in scalable milligram to gram quantities for high-throughput and bulk in vivo experiments.

Q: Is this research-grade Marstacimab biosimilar suitable for in vivo use?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Marstacimab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Marstacimab that binds TFPI; for research use only.